human immunoglobulin ig g1 kappa monoclonal antibody Search Results


trail r2  (ProSci Incorporated)
93
ProSci Incorporated trail r2
Trail R2, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/trail r2/product/ProSci Incorporated
Average 93 stars, based on 1 article reviews
trail r2 - by Bioz Stars, 2025-03
93/100 stars
  Buy from Supplier
human immunoglobulin g1 kappa  (Millipore)
86
Millipore human immunoglobulin g1 kappa
Percentage survival was monitored using the xCELLigence RTCA of cetuximab-sensitive (Cet Sen ) cell lines ( a ), acquired cetuximab-resistant (Acq Res ) ( b ) and intrinsically cetuximab-resistant (Int Res ) cell lines which were either HPV-negative ( c ) or HPV-positive ( d ), until 48 h after treatment. Tumour cells were either treated with an isotype control <t>(IgG1κ)</t> or cetuximab [2 µg/ml], with or without healthy donor-derived NK cells (effector to target (E:T) ratio of 5:1) under both normoxic and hypoxic conditions. Fraction of ADCC induced killing was obtained by subtraction of the means of cetuximab and NK cells from cetuximab alone condition ( e ). Effect of hypoxia was determined within the different cetuximab resistance groups ( f ) and HPV status ( g ) within each group. Graphs represent mean ± SEM for each time point of follow up. Statistical significance was tested using a linear mixed model with Tukey’s pairwise comparison. NS not significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001.
Human Immunoglobulin G1 Kappa, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human immunoglobulin g1 kappa/product/Millipore
Average 86 stars, based on 1 article reviews
human immunoglobulin g1 kappa - by Bioz Stars, 2025-03
86/100 stars
  Buy from Supplier
human immunoglobulin g1 kappa igg1κ monoclonal antibody  (MedImmune llc)
86
MedImmune llc human immunoglobulin g1 kappa igg1κ monoclonal antibody
Percentage survival was monitored using the xCELLigence RTCA of cetuximab-sensitive (Cet Sen ) cell lines ( a ), acquired cetuximab-resistant (Acq Res ) ( b ) and intrinsically cetuximab-resistant (Int Res ) cell lines which were either HPV-negative ( c ) or HPV-positive ( d ), until 48 h after treatment. Tumour cells were either treated with an isotype control <t>(IgG1κ)</t> or cetuximab [2 µg/ml], with or without healthy donor-derived NK cells (effector to target (E:T) ratio of 5:1) under both normoxic and hypoxic conditions. Fraction of ADCC induced killing was obtained by subtraction of the means of cetuximab and NK cells from cetuximab alone condition ( e ). Effect of hypoxia was determined within the different cetuximab resistance groups ( f ) and HPV status ( g ) within each group. Graphs represent mean ± SEM for each time point of follow up. Statistical significance was tested using a linear mixed model with Tukey’s pairwise comparison. NS not significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001.
Human Immunoglobulin G1 Kappa Igg1κ Monoclonal Antibody, supplied by MedImmune llc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human immunoglobulin g1 kappa igg1κ monoclonal antibody/product/MedImmune llc
Average 86 stars, based on 1 article reviews
human immunoglobulin g1 kappa igg1κ monoclonal antibody - by Bioz Stars, 2025-03
86/100 stars
  Buy from Supplier
human immunoglobulin g1 kappa igg1κ moa  (Janssen)
86
Janssen human immunoglobulin g1 kappa igg1κ moa
Percentage survival was monitored using the xCELLigence RTCA of cetuximab-sensitive (Cet Sen ) cell lines ( a ), acquired cetuximab-resistant (Acq Res ) ( b ) and intrinsically cetuximab-resistant (Int Res ) cell lines which were either HPV-negative ( c ) or HPV-positive ( d ), until 48 h after treatment. Tumour cells were either treated with an isotype control <t>(IgG1κ)</t> or cetuximab [2 µg/ml], with or without healthy donor-derived NK cells (effector to target (E:T) ratio of 5:1) under both normoxic and hypoxic conditions. Fraction of ADCC induced killing was obtained by subtraction of the means of cetuximab and NK cells from cetuximab alone condition ( e ). Effect of hypoxia was determined within the different cetuximab resistance groups ( f ) and HPV status ( g ) within each group. Graphs represent mean ± SEM for each time point of follow up. Statistical significance was tested using a linear mixed model with Tukey’s pairwise comparison. NS not significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001.
Human Immunoglobulin G1 Kappa Igg1κ Moa, supplied by Janssen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human immunoglobulin g1 kappa igg1κ moa/product/Janssen
Average 86 stars, based on 1 article reviews
human immunoglobulin g1 kappa igg1κ moa - by Bioz Stars, 2025-03
86/100 stars
  Buy from Supplier

Image Search Results


Percentage survival was monitored using the xCELLigence RTCA of cetuximab-sensitive (Cet Sen ) cell lines ( a ), acquired cetuximab-resistant (Acq Res ) ( b ) and intrinsically cetuximab-resistant (Int Res ) cell lines which were either HPV-negative ( c ) or HPV-positive ( d ), until 48 h after treatment. Tumour cells were either treated with an isotype control (IgG1κ) or cetuximab [2 µg/ml], with or without healthy donor-derived NK cells (effector to target (E:T) ratio of 5:1) under both normoxic and hypoxic conditions. Fraction of ADCC induced killing was obtained by subtraction of the means of cetuximab and NK cells from cetuximab alone condition ( e ). Effect of hypoxia was determined within the different cetuximab resistance groups ( f ) and HPV status ( g ) within each group. Graphs represent mean ± SEM for each time point of follow up. Statistical significance was tested using a linear mixed model with Tukey’s pairwise comparison. NS not significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001.

Journal: British Journal of Cancer

Article Title: Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status

doi: 10.1038/s41416-020-0934-3

Figure Lengend Snippet: Percentage survival was monitored using the xCELLigence RTCA of cetuximab-sensitive (Cet Sen ) cell lines ( a ), acquired cetuximab-resistant (Acq Res ) ( b ) and intrinsically cetuximab-resistant (Int Res ) cell lines which were either HPV-negative ( c ) or HPV-positive ( d ), until 48 h after treatment. Tumour cells were either treated with an isotype control (IgG1κ) or cetuximab [2 µg/ml], with or without healthy donor-derived NK cells (effector to target (E:T) ratio of 5:1) under both normoxic and hypoxic conditions. Fraction of ADCC induced killing was obtained by subtraction of the means of cetuximab and NK cells from cetuximab alone condition ( e ). Effect of hypoxia was determined within the different cetuximab resistance groups ( f ) and HPV status ( g ) within each group. Graphs represent mean ± SEM for each time point of follow up. Statistical significance was tested using a linear mixed model with Tukey’s pairwise comparison. NS not significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001.

Article Snippet: After overnight incubation, cetuximab [2 µg/ml] or human immunoglobulin G1 kappa (IgG1κ, [2 µg/ml]) (Sigma, 5154), as an isotype control was added.

Techniques: Derivative Assay